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OBJECTIVES: There has been a growing concern about the economic burden of
work incapacity due to mental health problems; meanwhile studies examining the
employer’s perspective are still scarce. This study aims to propose a rationale to
estimate the burden of mental health problems in Brazilian corporations.
METHODS:Data from an observational study investigating absenteeism due to sick
leaves in a Brazilian bank were used to build a costing estimation model (total
number of employees, average number of sick days per employee, and proportion
of sick days due to mental ill health). These data were combined with average wage
and turnover rate national statistics and published data on presenteeism due to
mental health problems. RESULTS: Based on n7499 workers, 3.36 annual sick
days per employee, a proportion of sick days attributable to mental health disor-
ders of 15.58%, and a mean daily wage of 51.33BRL, the costing model projected
annual costs due to absenteeism of 201,534BRL. If presenteeism is included in the
costing estimation, using a previously published presenteeism/absenteeism ratio
of 4.0 (for depressed workers), costs due to presenteeism would represent
806,138BRL per year. There is a lack of Brazilian observational studies assessing
turnover rates and associated costs. National rates according to economic sector
were employed to estimate the impact of turnover of mental ill workers (Service
Industry4.15% in 2010) and a turnover cost of 3 times the average monthly cost
per employee were used as a proxy. Turnover costs would incur in additional
115,500BRL per year. The annual economic burden of mental health disorders un-
der the employers perspective was estimated in 1,123,173BRL. CONCLUSIONS: The
cost of mental ill health to employers, particularly the cost of productivity losses
due to lower performance of employees at work (presenteeism), can represent a
significant burden for companies and society.
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OBJECTIVES:Mental illnesses in Pakistan are at rise. Decade long terrorism, suicide
bombing, recent floods, political uncertainty and transition to market economy are
some of the key factors that are contributing to increasing mental illnesses in the
country. This study emphasizes the importance of economic consequences of
mental illness in Pakistan and provides estimates of cost on mental illness in the
country. METHODS: Aga Khan University Hospital patient records of psychiatry
clinics inpatient (N727) and outpatient (N1458) data for the year 2005-06 were
classified into ten ICD-10 classification. For each category of mental illness the
direct cost included consultation fee, diagnostics, bed charges, laboratory charges
medication and procedure. The indirect costs on travel and productivity losses are
being estimated drawing a stratified random sample for both inpatient and day
care dataset. RESULTS: Mental illnesses categories 2(Schizophrenia (N227) and
3(mood/depressive disorder (N415) accounted for 82% of burden of mental ill-
nesses in inpatient care. While in day care 2(Schizophrenia 3(mood/depressive
disorder and 4(Panic/OCD) accounted for 75 % of the burden of mental illnesses in
Pakistan. Mean cost for all categories in inpatient care is Pak Rs. 21701 per treat-
ment episode. Illnesses category 8 (anorexia) was the most costly (MeanRs.71687)
and category 1(dementia and other organic disorders were relatively less expensive
to treat (MeanPak Rs.1183). CONCLUSIONS: Initial findings suggest the economic
burden of mental illnesses is alarmingly high and its treatment is unaffordable by
many families in the country. This might result in denied or delayed care. Using
country level available data on burden of mental illness the economic impact of
mental illnesses in Pakistan will be estimated. We will also explain socio-economic
determinates of mental illnesses.
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OBJECTIVES: There is little data describing current practice in the clinical manage-
ment of patients with psychosis and co-occurring substance use and the associated
costs. In the UK, standard psychiatric care is based on the care programme ap-
proach and includes community and hospital-based treatment. Inpatient psychi-
atric treatment is the key cost driver of psychiatric care. This study aimed to de-
scribe practice-based patient-level costs of inpatient psychiatric treatment for NHS
patients with psychosis and co-occurring substance use. METHODS: Resource use
data of inpatient psychiatric treatment were collected from the medical records of
327 patients recruited in the MIDAS trial, a randomised controlled trial of an ex-
perimental intervention programme (integrated motivational interviewing and
cognitive-behaviour therapy, MiCBT) plus standard care or standard care alone.
Using the hospital perspective, data were collected from trial entry until end of
2-year trial follow-up (between 2004 to 2009). Unit costs were assigned, based on
NHS Reference Costs 2008/09 and PSSRU 2009. Data were analysed using descrip-
tive statistics and variations around the costs were obtained. RESULTS: Of the 327
patients, 95 patients (29%) experienced at least one episode of hospitalisation, with
a mean of 85 inpatient days (95% CI: 65 – 105, median 42, range 2 - 568) per hospi-
talised patient. Total cost for these 95 patients was £2.43million (UK £2008/09) over
8,108 inpatient days. Mean cost per hospitalised patient was £25,547 (95% CI:
£18,453 – £32,640, median £12,180, range £580 – £273,208). Cost components com-
prised: acute psychiatric admission (total 6,428 days, £1.86million), psychiatric re-
habilitation admission (total 621 days, £165,186), psychiatric long-stay admission
(total 434 days, £91,574), psychiatric ICU admission (total 57 days, £32,832) and
psychiatric forensic medium secure unit admission (568 days, £273,208).
CONCLUSIONS: This study provided practice-based data describing patient-level
costs associated with standard NHS care of inpatient psychiatric treatment for
patients with psychosis and co-occurring substance use.
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OBJECTIVES: Pharmacological strategies for schizophrenia have received increas-
ing attention due to the development of new and costly drug therapies. To estimate
the direct healthcare and non-healthcare cost of schizophrenia and to simulate
cost reductions potentially obtained with a new pharmacogenomics treatment, in
a cohort of patients newly diagnosed with schizophrenia, over the first 5 years
following their diagnosis. METHODS: A microsimulation Monte-Carlo Markov
model was used. Six discrete disorder states defined the Markov model: 1): first
episode (FE); 2) low dependency state (LDS); 3) high dependency state (HDS); 4)
Stable state (Stable); 5) Well state (Well); and 6) Death state (Death). Costs and
individual probabilities of transition were estimated from the Régie de l’assurance
maladie du Québec and Med-Echo databases. RESULTS: A total of 14,320 individu-
als were identified in the study cohort as newly diagnosed patients with schizo-
phrenia. Over the first 5 years following diagnosis the mean cost per person was
estimated at $36,701 (95%CI: 36,264 to 37,138). The direct health care cost accounted
for 56.2% of the total cost, welfare assistance for 34.6% and long term care facilities
for 9.2%. On the direct health care cost, hospitalisation cost accounted for 64.6%,
medical cost for 11.4% and drug-related cost for 24%. In the case where a new
pharmacogenomic treatment with 20% increase of effectiveness will be available,
the direct healthcare and non-health care costs can be reduced up to 14.2%.
CONCLUSIONS: This model is the first Canadian model incorporating transition
probabilities adjusted for individual risk-factor profiles and costs using real-life
data. Our results indicate that a new pharmacogenomics treatment could possibly
reduce hospitalization and long-term care facility costs while potentially enabling
patients to return to active employment that would in turn contribute to the re-
duction of the welfare assistance cost.
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OBJECTIVES: People addicted to opioids contribute a significant burden to society,
both in terms of quality of life (QoL) and economic consequences. Untreated users
are more likely to be out of work, commit crimes and require healthcare resources.
Treating patients has been demonstrated to reduce these factors. However, some
users receiving formal care continue to misuse that treatment, leading to other
significant consequences for society. This study evaluated the potential impact of
a novel formulation (buprenorphine/naloxone; suboxone), aimed at mitigating
misuse and diversion. Increasing the currently limited number of treatments avail-
able will likely increase the number of people in treatment. The objective was to
assess cost-effectiveness of two approaches to managing opioid users, buprenor-
phine/naloxone and methadone, and, further, to compare the use of any treatment
against no treatment. METHODS: A cost-effectiveness model was built, incorpo-
rating the costs and benefits associated with each treatment. Healthcare unit cost
data were taken from published data and databases, including NHS Reference
Costs 2009-2010 and PSSRU Unit Costs of Health and Social Care 2010. Crime costs
were taken from Home Office publications. Crime and hospitalisation rates, by
treatment, were taken from an observational study of 109 patients in Scotland.
Health related QoL figures, by treatment, were taken from an SF-36 questionnaire
study. RESULTS: Over 6 months, it was estimated that savings associated with
reduced crime (buprenorphine/naloxone versus methadone) were £2129, and sav-
ings from reduced health care visits were £1409. Based on a combination of mor-
tality and QoL improvements, patients on buprenorphine/naloxone were shown to
gain 0.087 QALYs compared to those receiving methadone. CONCLUSIONS: The
model showed that the cost implications of crime, hospitalisation and misuse and
diversion were key drivers of the results. Use of buprenorphine/naloxone resulted
in a saving of £3538 due to reduced crime and hospitalisations, whilst providing a
benefit to QoL.
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OBJECTIVES: The objective of this exploratory analysis was to assess the cost-
effectiveness of quetiapineXR as monotherapy compared to other key drug treat-
ments in MDD patients, who have failed on previous therapy.METHODS:A Markov
Model with one week cycles was used to assess the cost effectiveness of quetiap-
ineXR treatment over 52 weeks. Key outcomes were: response rates, costs and
Incremental Cost-Effectiveness Ratios (ICERs) for second line monotherapy. The
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obtained clinical trials data for all drugs represented first line therapy for MDD. For
this reason, response rates were down-adjusted to reflect their use as a second-line
therapy, with each response rate being multiplied by a factor obtained from the
STAR*D- trial. Since response rates were reported at a constant rate in clinical
trials, they were converted into “weekly probabilities” of response. Patients enter-
ing second-line monotherapy were not differentiated by switch or add-on.
QuetiapineXR(150mg) was compared with venlafaxineXR(150mg),
escitalopram(10mg) and bupropionXL(300mg), which are considered to be the most
relevant monotherapy comparators in Turkey. One-way sensitivity analyses were
conducted on key model parameters to evaluate the robustness of the model.
RESULTS: The response rates at any time over 52 weeks were 22.5% for quetiap-
ineXR, venlafaxineXR 17.8%, escitalopram 12.6% and bupropionXL 10.7%. In terms
of incremental cost per additional second-line responder, quetiapineXR was found
to be dominant (more effective and less costly) versus venlafaxineXR (-353.55€) and
quetiapineXR was cost-effective (more effective and more costly) versus escitalo-
pram (1785.43€) and bupropionXL (652.90€). The cost per responder of quetiap-
ineXR(48.85€) was less than venlafaxineXR(62.68€), escitalopram(73.20€) and
bupropionXL(95.52€). CONCLUSIONS: This exploratory analysis demonstrated that
in patients with MDD who have failed on previous antidepressant therapy, quetia-
pineXR 150mg as monotherapy was found to be cost-effective compared to escita-
lopram and bupropionXL, in terms of cost per responder, and was dominant when
compared to venlafaxineXR, demonstrating higher efficacy at lower costs.
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OBJECTIVES: In schizophrenia, medication adherence is critical to achieve better
patient outcomes and to avoid relapses, which are responsible for a significant
proportion of total healthcare costs for this chronic illness. The aim of this study
was to assess the cost-effectiveness of olanzapine long-acting injection (OLAI)
compared with risperidone long-acting injection (RLAI) in patients with schizo-
phrenia in Spain. METHODS: A discrete event simulation (DES) model was devel-
oped from a Spanish healthcare system perspective to estimate clinical and eco-
nomic outcomes for patients with schizophrenia over a five year period. Patients
who had earlier responded to oral medication and have a history of relapse due to
adherence problems were considered. These patients faced the option to be treated
with either OLAI or RLAI. In the absence of a head-to-head clinical trial, discontin-
uation and relapse rates were obtained from an indirect comparison of open-label
studies. The model accounted for age, gender, risks of relapse and discontinuation,
relapse management, hospitalization, treatment switching and adverse events.
Direct medical costs (year 2011) and outcomes including relapse avoided, life years
(LYs), and quality-adjusted life years (QALYs) were discounted at a rate of 3%.
RESULTS: When comparing RLAI and OLAI, the model predicts that OLAI would
decrease 5-year costs by €2940, and results in a QALY and LY gain of 0.07 and 0.04,
respectively. Patients on OLAI had fewer relapses compared to RLAI (1.39 vs. 1.82)
and fewer discontinuations (1.22 vs. 1.71). Sensitivity analysis indicated that the
study was robust and conclusions were largely unaffected by changes in a wide
range of parameters. CONCLUSIONS: The present evaluation results in OLAI being
dominant over RLAI, meaning that OLAI represents a more effective and less costly
alternative compared to RLAI in the treatment of patients with schizophrenia in
the Spanish setting.
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OBJECTIVES: To determine the cost-effectiveness of agomelatine for major depres-
sion in adults. METHODS: A hypothetical cohort was simulated from a discrete
event simulation (DES) model developed to describe the course of disease in indi-
viduals. Model inputs included Thai data on disease parameters and costs while
impact measures are derived from systematic reviews and meta-analyses of the
international literature. The costs for treatment of adverse events of these drugs,
insomnia and sexual dysfunction, were taken into account in the model. Antide-
pressant drugs were analyzed for treatment of episodes (12-24 weeks) plus a con-
tinuation phase (6-9 months) and for maintenance treatment over 2 years of follow
up. Results are presented as Thai Baht cost (THB) per quality adjusted life year
(QALY) gained, compared to a matrix comparators (50 % venlafaxine and 50%
escitalopram). RESULTS: Preliminary results show that daily costs for average dose
of agomelatine (25 mg), escitalopram (10 mg) and venlafaxine (150 mg) are 52, 60, 98
THB, respectively. Total cost of agomelatine is 52,000 THB and total cost of matrix
comparator is 76,000 THB. Health benefit measures of agomelatine and the matrix
comparator are almost the same at 2,500 QALY gained. Agomelatine is considered
a cost-effective intervention with an ICER of 400,000 (95% uncertainty range:
410,000- 390,000) THB per QALY gained. The ICER is less than three times Gross
Domestic Product (GDP) per capita in Thailand of 420,000 THB. CONCLUSIONS:
Agomelatine is the most cost-effective treatment option for episodic continuation
and maintenance treatment of major depression when compared with venlaflax-
ine and escitalopram. As recommended by the World Health Organization (WHO)
for cost-effectiveness health intervention, agomelatine is an affordable option for
treatment of major depressive episodes in Thailand.
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OBJECTIVES: Paliperidone ER Extended Release OROS (ER) is a relatively new atyp-
ical antipsychotic for the treatment of schizophrenia. The objective is, based on a
previously published model, to analyze the clinical and economic effects of Pali-
peridone ER in Spain compared to olanzapine oral and aripiprazole. METHODS: An
existing discrete event simulation model was adapted to reflect the treatment of
schizophrenia in Spain in terms of costs, resource use and treatment patterns.
Inputs for the model were derived from clinical trial data, literature search, data-
base analysis, and interviews with local clinical experts. The time horizon is five
years and Spanish discount rates were applied. Outputs included direct medical
costs and Quality Adjusted Life-Years (QALYs). Sensitivity analyses were con-
ducted to assess the uncertainty surrounding incremental outcomes and to iden-
tify model drivers, by performing probabilistic sensitivity analysis (PSA) and ordi-
nary least squares analysis (OLSA). RESULTS: The mean (95% CI) incremental
QALYs compared to olanzapine is 0.033 [-0.14, 0.30] and compared to aripiprazole
0.029 [-0.11,0.30]. The corresponding mean incremental costs (95% CI) are -€ 1,425
[-€ 10,247, €3,084] and -€ 759 [-€ 10,479, € 3,404] respectively. Based on the PSA, the
probability that paliperidone ER is cost-saving and improves QALYs compared to
olanzapine and aripiprazole is 76% and 72% respectively. Paliperidone ER was es-
timated to have 80% and 81% probability of being cost effective compared to olan-
zapine at a willingness to pay of €20,000 and €30,000 and 73% and 74% compared to
aripiprazole respectively. OLSA identified drug acquisition costs, side effects and
risk of relapse to be major model drivers. CONCLUSIONS: Based on differences in
drug acquisition costs, side effects and risk of relapse, the model predicts that in
Spain paliperidone ER provides QALY gains and cost savings compared with oral
olanzapine and aripiprazole with a probability of 76% and 72% respectively.
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OBJECTIVES: To evaluate cost-utility of amisulpride compared with first genera-
tion antipsychotics (FGA) in treatment of schizophrenia in adult patients in Poland.
METHODS: A decision-tree model was used to estimate utilities and costs of treat-
ment of amisulpride therapy in comparison to FGA (antipsychotics, management
of main antipsychotics’ adverse events - extrapyramidal symptoms’ (EPS) and
health care costs). The FGA group included the following drugs: haloperidol, pera-
zine and flupenthixol. Analysis was performed from the National Health Fund
(NHF) perspective with a time horizon of 1 year. The range of possible events in the
model included: therapy discontinuation (regardless of reason), EPS occurrence,
schizophrenia relapse and suicide. Range of events was assumed to be the same for
amisulpride and FGA but probabilities of those events varied between antipsychot-
ics. Based on systematic review of RCTs amisulpride is more effective than FGA in
terms of compliance rate and in reduction of both the risk of relapse and occur-
rence of EPS. A probabilistic sensitivity analysis was performed to estimate the
probability that amisulpride is cost effective in Polish conditions (threshold about
100,000 PLN/QALY). RESULTS: From the NHF perspective amisulpride compared
with FGA was more effective (	QALY  0.004) and it was cheaper (comparing to
flupenthixol) or cost-effective (ICUR1 079/QALY PLN and ICUR31 810/QALY PLN
in comparison to haloperidol and perazine, respectively). The calculated probabil-
ity that amisulpride is more effective than any of FGA was 100%, while the proba-
bility that it is also cost-effective varied between 68% for perazine to 83% for
flupenthixol. CONCLUSIONS: Treatment of schizophrenia with amisulpride is a
cost-effective option in comparison to FGA in Poland. The obtained difference in
QALY is very small, but reduced risk of relapse and necessity of hospitalization due
to better effectiveness of amisulpride and reduced occurrence of EPS results in a
better cost benefit outcome for amisulpride compared to FGA.
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OBJECTIVES: Paliperidone palmitate long-acting injection (PP-LAI) has recently
been approved in Europe for treatment of schizophrenia as an alternative to olan-
zapine pamoate (OLZ-LAI). Their relative cost-effectiveness has not yet been ade-
quately assessed. The purpose was to compare costs and outcomes of these two
LAIs in treating schizophrenia in Norway. METHODS: A previously validated and
published decision analytic model estimating costs and outcomes of treatment
schizophrenia over a 1-year time horizon was adapted to simulate clinical practice
patterns in Norway. Drugs of interest were PP-LAI and OLZ-LAI. Clinical inputs
were derived from the literature and experts, and costs from standard lists. Clinical
outcomes included days in remission, hospitalizations, hospitalized days, and
quality-adjusted life-years (QALYs). Costs were derived from the public health care
provider perspective and reported in 2010 Norwegian kroner (NOK; €17.8 kroner,
USD$15.4 kroner). The pharmacoeconomic outcome was the incremental cost
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